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Background: Hypoxia- and Myc-dependent transcriptional regulatory pathways are frequently deregulated in cancer
cells. These pathways converge in many cellular responses, but the underlying molecular mechanisms are unclear.
Methods: The ability of Miz-1 and Arnt to interact was identified in a yeast two-hybrid screen. The mode of interaction
and the functional consequences of complex formation were analyzed by diverse molecular biology methods, in vitro.
Statistical analyses were performed by Student’s t-test and ANOVA.
Results: In the present study we demonstrate that the aryl hydrocarbon receptor nuclear translocator (Arnt), which is
central in hypoxia-induced signaling, forms a complex with Miz-1, an important transcriptional regulator in Myc-mediated
transcriptional repression. Overexpression of Arnt induced reporter gene activity driven by the proximal promoter of the
cyclin-dependent kinase inhibitor 2B gene (CDKN2B), which is an established target for the Myc/Miz-1 complex. In
contrast, mutated forms of Arnt, that were unable to interact with Miz-1, had reduced capability to activate transcription.
Moreover, repression of Arnt reduced endogenous CDKN2B expression, and chromatin immunoprecipitation
demonstrated that Arnt interacts with the CDKN2B promoter. The transcriptional activity of Arnt was counteracted by
Myc, but not by a mutated variant of Myc that is unable to interact with Miz-1, suggesting mutually exclusive interaction
of Arnt and Myc with Miz-1. Our results also establish CDKN2B as a hypoxia regulated gene, as endogenous CDKN2B
mRNA and protein levels were reduced by hypoxic treatment of U2OS cells.
Conclusions: Our data reveal a novel mode of regulation by protein-protein interaction that directly ties together, at
the transcriptional level, the Myc- and hypoxia-dependent signaling pathways and expands our understanding of the
roles of hypoxia and cell cycle alterations during tumorigenesis.
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Hypoxia inducible factors (HIFs) are transcriptional reg-
ulators essential for cellular responses to low O2 levels
(hypoxia). The HIFs belong to the family of helix-loop-
helix (HLH)-Per-Arnt-Sim (PAS) factors, which act as
sensors for environmental and developmental signals.
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reproduction in any medium, provided the orand the ubiquitously expressed dimerization partner pro-
tein, the aryl hydrocarbon receptor nuclear translocator
(Arnt). Arnt is essential in multiple cellular regulatory
pathways, as it functions as an obligate heterodimerization
partner for many HLH-PAS proteins. Three Hifα-subunits
are known, of which Hif1α and Hif2α are the best charac-
terized. (Hif1α and Hif2α will commonly be referred to as
Hifα in this paper). In the canonical hypoxic transcriptional
response, Hif1α and Hif2α are stabilized at low O2 tension
and translocate to the nucleus where they bind to hypoxia
response elements (HREs) together with Arnt (reviewed intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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as in for instance genes that promote cell survival at low-
O2 conditions (e.g. vascular endothelial growth factor and
glucose transporter-1, which induce angiogenesis and
glycolysis respectively [3]). However, Hif1α also confers
transcriptional repression, and is then typically indirectly
recruited to target genes via protein interactions [4,5].
Myc directs changes in metabolism, protein synthesis
and cell proliferation through its transcriptional activity
[6]. In the course of transcriptional activation, Myc in-
teracts with its partner Max at E-box elements within
target gene promoters. In contrast, when Myc acts as a
transcriptional repressor, it interacts indirectly with DNA
through other transcription factors [7]. One such factor is
Miz-1 (Myc-interacting zinc finger protein 1). Miz-1 typic-
ally interacts with initiator (INR)-like elements in close
proximity to the transcriptional start site and activates ex-
pression of target genes. Some of the first targets identified
for Miz-1 were genes encoding cyclin-dependent kinase
(CDK) inhibitors (CDKIs) (e.g. CDKN1A and CDKN2B),
and consequently Miz-1 inhibits cell cycle progression
[8-10]. When Myc-levels rise within the cell, Myc, in com-
plex with Max, binds to Miz-1 and displaces the co-
activator p300 with subsequent loss of the transcriptional
potential of Miz-1 [10]. Although Miz-1 was first identi-
fied as a Myc-interacting protein and inducer of cell cycle
arrest [11], Miz-1 also promotes cell survival and prolifer-
ation in some cellular contexts [12,13]. Myc is the only
bHLH factor hitherto known to interact with Miz-1, but
Miz-1 interacts with many other types of proteins, and
functions of Miz-1 that are independent of Myc have been
recognized [14-17].
Myc and hypoxia dependent transcriptional signaling
is frequently deregulated in cancer cells, and importantly,
these pathways are closely integrated in several processes
that are altered in tumors (e.g. carbon metabolism, protein
synthesis and cell cycle progression [18,19]). Myc and
HIFs converge on many gene promoters, and can either
act in concert or counteract each other. Generally, the lit-
erature suggest that Hifα enhances Myc action on genes
that are involved in angiogenesis and glycolysis, but op-
poses Myc on promoters controlling the expression of
genes implicated in DNA repair, mitochondrial biogenesis
and cell proliferation [20]. For example, Hif1α displaces
c-Myc from Sp-1 leading to repression of DNA repair
genes [4,5]. With regard to genes controlling cell cycle
progression, the scenario is more complex, and the under-
lying mechanisms less well understood. Collectively, the
existing literature strongly indicates that the final tran-
scriptional outcome will vary depending on the hypoxic
environment and on cellular and promoter context [1,21].
Moreover, the transcriptional response and subsequent ef-
fects on cell cycle progression most likely also depend on
whether the cell expresses predominantly Hif1α or Hif2α[22]. In this study we present a molecular interaction that
might function as a molecular hub that unites hypoxia-
and Myc-dependent signaling. We demonstrate that Arnt
is an interaction partner for Miz-1, and that Arnt has a
functional role in the regulation of CDKN2B, a known tar-
get for the Myc/Miz complex.
Results
Arnt and Miz-1 interact
We initially observed the interaction between Miz-1 and
Arnt in a yeast two-hybrid screen where a deletion mutant
of Arnt lacking the transactivation domain (ArntΔQ; amino
acid (aa) 1–618) was found to interact with the C-terminal
part of Miz-1 (aa 470–794; data not shown). Diverse Arnt
constructs (schematically presented in Figure 1A) were
tested for their ability to interact with Miz-1 in mammalian
cells. Cos-1 cells were transiently transfected with Arnt/Flag
and Miz-1/GFP and, as demonstrated in Figure 1B (upper
panel), Arnt precipitated together with Miz-1 suggesting
that these two factors interact in vivo. For the inter-
action to occur, the basic HLH (bHLH) domain of Arnt
was required, but not the PAS domain (Figure 1B, upper
panel). Complex formation between Miz-1 and Myc re-
quires amino acids V393, V394, K397 and S405 in helix
II of the HLH-domain of Myc [14]. Alignment of Myc
and Arnt demonstrated that with regard to charge and
hydrophobicity, a similar interactions surface is present
in helix II of Arnt by the amino acids L114, T115, R118
and S126 (Figure 1A). Mutation of amino acid T115 and
S126 (2xmut; T115D/S126A) decreased the ability of Arnt
to interact with Miz-1, and mutation of all four amino acids
(4xmut; L114A/T115D/R118G/S126A) reduced complex
formation below the detection limit of the assay (Figure 1B,
upper panel), pointing to a similar mode of interaction be-
tween Arnt and Miz-1 as between Myc and Miz-1. Control
experiments demonstrated comparable expression levels of
wt Arnt and the different mutants (Figure 1B, middle
panel), and moreover that Miz-1 was precipitated at similar
levels in all samples, although slightly less in lanes 1 and 6
(Figure 1B, lower panel). Experiments designed to map the
domain(s) of Miz-1 involved in complex formation failed,
presumably because the different deletion constructs exhib-
ited different cellular localization (i.e. cytoplasmic, nuclear
or perinuclear; data not shown). Work by Peukert and col-
leagues indicate that Miz-1 lacks a functional nuclear
localization signal, however they found that overexpression
of Myc induces a redistribution of Miz-1 from the cyto-
plasm to the nucleus [11]. To investigate whether Arnt
would alter the localization of Miz-1, Arnt/CFP and Miz-1/
Flag were expressed in HEK293 cells. Consistent with
previous reports, Arnt/CFP localized exclusively to the
nucleus whereas Miz-1/Flag was distributed diffusely
throughout the cell when expressed singlehandedly
(Figure 1C) [11,23,24]. Notably, in cells where Arnt/CFP
Figure 1 (See legend on next page.)
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Figure 1 Arnt and Miz-1 interact. A) Schematic representation of motifs within native and mutant constructs of Arnt. The human Arnt used in
this study consists of 774 amino acids and the location of its helix-loop-helix (bHLH), Per-Arnt-Sim (PAS) and the glutamine rich (Q-rich) domains
are shown. The amino acid mutations in “2xmut” and “4xmut” are indicated in bold in the Helix II sequence. B) Miz-1/GFP and wt or mutated variants
of Arnt/Flag were overexpressed as indicated. Immunoprecipitation (IP) was performed using anti-GFP and immunoblotting (IB) was performed with
anti-Flag (upper panel). Input (4%) was run on a parallel gel and IB was performed with anti-Flag (middle panel). In order to verify Miz-1/GFP IP in the
different samples, the co-IP membrane was stripped and incubated with anti-GFP (lower panel). C) HEK293 cells were co-transfected with Miz-1/Flag
and Arnt/CFP. Cells were subjected to confocal microscopy to visualize Texas-red fluorescence (for Miz-1/Flag; left panel) or cyan fluorescence (for
Arnt/CFP; middle panel). The right panel shows the merged image. The borders of the cytoplasm of the cells are marked in white, while the borders of
nuclei are marked in yellow.
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tioned from the cytoplasm to the nucleus (Figure 1C). Al-
though co-localization of the two proteins in HEK293
cells was not observed under these experimental condi-
tions, this result suggests that overexpression of Arnt in-
duces a cellular redistribution of Miz-1 and indicates a
functional significance for the Miz-1/Arnt complex.
Arnt induces reporter gene expression from the
CDKN2B promoter
The CDKN2B promoter is an established target for the
Miz-1/Myc complex. Whereas Miz-1 activates this pro-
moter, Myc acts as a repressor through interaction with
Miz-1 and displacement of p300/CBP [9,10]. To explore
the possibility that Arnt might affect this Myc/Miz-1-
dependent transcriptional regulation, Arnt was overex-
pressed in human osteosarcoma U2OS cells together with
a luciferase reporter construct containing 35 nucleotides
upstream of the transcriptional start site of CDKN2B
(−35CDKN2B/luc, [25]). This construct does not contain
a consensus Arnt binding site, or a canonical HRE [26].
U2OS cells are frequently used in functional studies that
aim to understand the molecular mechanisms underlying
hypoxic transcriptional responses as this cell line respond
well to low O2 levels. As expected, based on the literature
[14], Miz-1 induced luciferase activity from the CDKN2B
promoter (Figure 2A). Likewise, Arnt caused an induc-
tion of luciferase activity from this promoter construct
(Figure 2A). The stimulatory effects of Arnt and Miz-1
on this promoter construct did vary between experiments;
however, we always observed significantly enhanced re-
porter gene activity after Arnt and Miz-1 overexpression.
Mutation of the amino acids in Arnt required for Miz-1
interaction (2xmut, 4xmut) led to decreased reporter gene
activity, but apparently, the low level of complex formation
between Miz-1 and 2xmut Arnt and, although not detect-
able above the background in the co-IP assay, 4xmut Arnt
was sufficient to drive reporter gene expression to a cer-
tain level in this system (Figure 2B). As stated above, Myc
inhibits Miz-1 induced transcription from the CDKN2B
promoter. The results presented in Figure 2C show that
Myc also repressed Arnt-dependent reporter gene expres-
sion from this promoter, and moreover, that a mutatedversion of Myc that is unable to interact with Miz-1
(MycV394D) [14] failed to inhibit Arnt-induced transcrip-
tion (Figure 2C). Taken together, these experiments sup-
port the concept that Arnt induces transcription from the
CDKN2B promoter via interaction with Miz-1, and that
Myc counteracts this activity through competition for the
interaction surface of Miz-1.
Arnt interacts with the CDKN2B promoter
To establish whether Arnt interacts with the CDKN2B
promoter, chromatin-immunoprecipitation (ChIP) ana-
lyses combined with qPCR were performed. These ex-
periments demonstrated that Arnt is enriched on the
proximal CDKN2B promoter (Figure 3A) compared to a
distal region of the promoter (Figure 3B) in U2OS cells.
Since Arnt is an obligate partner of Hif1α and Hif2α,
and thus plays an important role in hypoxia regulated
gene expression [27,28], we cultured U2OS cells in 1%
O2 for 4 or 24 hours to examine whether hypoxic condi-
tions would affect binding of Arnt. Interestingly, recruit-
ment of Arnt to the proximal CDKN2B promoter was
reduced when the cells were cultured under hypoxia com-
pared to normoxic conditions (Figure 3A). Unfortunately,
with commercially available antibodies, we were not able to
determine the occupation of Miz-1 on the CDKN2B pro-
moter during hypoxia (or normoxia). Binding of Miz-1 to
the CDKN2B promoter in normoxic cells has been shown
previously [10,15]. As a control for hypoxia induced tran-
scription, primers spanning the HRE in the promoter of
phosphoglycerate kinase 1 (PGK-1) were employed to de-
termine Arnt interaction. As reported [29], Arnt was found
to bind to the HRE of PGK-1 at normoxia, and at increased
levels under hypoxic conditions (Figure 3C).
Hypoxia decreases CDKN2B expression
To further explore the potential role of O2 pressure in
the expression of CDKN2B, we examined whether hyp-
oxia affected CDKN2B endogenous protein and mRNA
levels. The protein level of CDKN2B decreased after 4 and
24 hours at 1% O2 compared to the expression at nor-
moxia (Figure 4A). Already after 2 hours, the CDKN2B
mRNA level was significantly reduced, and declined fur-
ther when the hypoxic exposure was prolonged to 16 or
Figure 2 Arnt activates transcription from the CDKN2B
promoter. A-C) U2OS cells were transfected in 12-well plates with
the reporter gene construct -35CDKN2B/Luc (300 ng) and expression
plasmids encoding Miz-1 (Miz1/pcDNA) or wt Arnt (Arnt/Flag/pCMV)
at the indicated concentrations (A), wt Arnt or mutated variants of
Arnt/Flag (Arnt (T115D/S126A)/Flag/pCMV denoted “2xmut” and Arnt
(L114A/T115D/R118G/S126A) /Flag/pCMV denoted “4xmut” (100 ng
each) (B), and wt Arnt and wt (Myc/pcDNA3) or a mutated variant
of Myc (V394D) (Myc (V394D)/pcDNA3) (100 ng each) as indicated
(C). The luciferase activity is presented as average +/− stdev, n = 9 in
A; n = 6 in B; n = 12 in C. Statistical analyses: (A) Student’s T-test,
(B) ANOVA (Bonferroni), (C) ANOVA (Dunnett’s T3); ***p≤ 0.001, ns:
non significant.
Figure 3 Arnt interacts with the CDKN2B promoter. ChIP
experiments were performed on extracts from U2OS cells using an
antibody (Ab) against Arnt or preimmune IgG as indicated. The cells
were cultured at normoxia (21% O2) or at hypoxia (1% O2) for 4 or
24 hours before harvested. qPCR was performed with primers
spanning the CDKN2B proximal promoter (−168/-19) (A), primers
spanning a distal CDKN2B promoter sequence (−3874/-3744) (B) and
primers spanning a hypoxia response element (HRE) of the PGK-1
proximal promoter (−75/+101) (C). The results are given as average
enrichment of the indicated promoter fragment +/− stdev, n = 6.
Statistical analyses: (A) ANOVA (Dunnett’s T3), (B-C) ANOVA
(Bonferroni); **P ≤ 0.01, *P≤ 0.05, ns: not significant.
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with the ChIP results in Figure 3, and indicate that as O2
levels fall, Arnt is released from the promoter leading to
decreased expression of CDKN2B. The mRNA expression
Figure 4 Expression of CDKN2B is decreased in response to
hypoxia. A-B) U2OS cells were cultured at normoxia (21% O2) or at
hypoxia (1% O2) for the time points indicated, and immunoblotting
for CDKN2B (A) as well as qRT-PCR analyses for CDKN2B (B) and
PGK-1 (C) were performed. Immunoblotting for the housekeeping
protein beta-actin was used as a loading control (A). The qRT-PCR
values were normalized to the expression of the housekeeping gene
HPRT-1, and are shown as average of relative fold change +/− stdev,
three independent experiments performed in duplicates (B and C).
Statistical analyses: (B) ANOVA (Bonferroni); (C) ANOVA (Dunnett’s T3);
***p≤ 0.001, *P≤ 0.05, ns: non significant.
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with the literature [29], increased during hypoxic treatment
(Figure 4C).
Repression of Arnt, Miz-1 and Hifα causes downregulation
of CDKN2B mRNA levels
Expression of siRNA against Arnt (siArnt) caused a signifi-
cant decrease in the CDKN2B mRNA expression, further
supporting a role for Arnt in transcriptional regulation
of this gene (Figure 5A, compare columns 1 and 3). Asexpected from previous studies [9,10], inhibition of Miz-1
also repressed the expression of CDKN2B (Figure 5A,
compare columns 1 and 5). Intriguingly, knockdown of
Hif1α and Hif2α also caused reduced CDKN2B mRNA
levels at normoxia (Figure 5A, compare column 1 with
column 7 and 9). The effect of siHif1α was significant,
despite the fact that the level of Hif1α protein at normoxia
was below the detectable threshold (Figure 5C, right
upper panel). In contrast, Hif2α was readily detectable at
normoxia in this cell line (Figure 5C, right lower panel), as
has also been reported previously [30]. In agreement with
the results in Figure 4, hypoxic treatment for 6 hours de-
creased CDKN2B mRNA levels with around 50-60% in
presence of control siRNA (Figure 5A, compare columns
1 and 2), and administration of siRNA against Arnt, Miz-1
and Hif2α under hypoxic conditions further repressed
CDKN2B expression (Figure 5A, compare lane 2 with
lanes 4, 6 and 10). In contrast, siHif1α had no significant
effect under hypoxic conditions compared to control
siRNA (Figure 5A, compare lanes 2 and 8).
Intriguingly, we found that Miz-1 mRNA levels were
suppressed in response to hypoxia (Figure 5B compare
lanes 5 and 6), as was the protein level (Figure 5C, left
lower panel). A comparable response was observed when
endogenous Miz-1 mRNA expression was determined in
response to hypoxia (Figure 5D), suggesting that this
gene is regulated by O2 tension and substantiating the
impact of Miz-1 as an important activator of CDKN2B
in the normoxic state. This effect might be cell line specific,
however, as a similar downregulation of Miz-1 mRNA in
response to hypoxia is not observed in HCT116 or WT-8
cells [22]. The gene encoding Miz-1 contains an HRE
element in the 5’ untranslated region as well as in intron 1,
and it remains to be determined whether HIFs interact
with these sequences. The mRNA levels of Arnt and
Hif1α were also slightly reduced in response to hypoxia
(Figure 5B, compare lanes 1 and 2 for Arnt and lanes 9
and 10 for Hif1α). However the corresponding protein
levels increased, as they did for Hif2α, and as previously
reported [31]. These results suggest that the Arnt/Miz-1
complex, possibly in association with Hifα, is involved
in CDKN2B gene regulation in U2OS cells. Further sup-
porting the scenario that such a complex has impact on
transcription from the CDKN2B promoter are the results
shown in Figure 5E, namely that Arnt-induced CDKN2B-
promoter dependent luciferase expression is inhibited as a
consequence of repressing Miz-1, Hif1α or Hif2α. All fac-
tors were relatively efficiently repressed by the correspond-
ing siRNA, both at the mRNA level and at the protein
level (Figure 5B and C).
Hypoxia leads to release of Myc from the CDKN2B promoter
Since Myc is an established inhibitor of CDKN2B ex-
pression, we hypothesized that Myc might replace Arnt
Figure 5 Inhibition of Miz-1, Arnt and Hifα expression reduces CDKN2B mRNA levels. A-C) U2OS cells were transfected with siRNA (10 nM)
against Arnt, Miz-1, Hif1α and Hif2α as indicated and cultured at normoxia (21% O2) or hypoxia (1% O2) for 6 hours. A) qRT-PCR analyses of
CDKN2B mRNA levels after administration of the different siRNAs are presented as relative fold changes compared to control siRNA at normoxia
(column 1). B) qRT-PCR analysis of mRNA expression of Arnt, Miz-1, Hif1α and Hif2α after siRNA treatment. The mRNA levels after administration
of the different siRNAs are presented as relative fold changes compared to control siRNA at normoxia for each specific mRNA species. C) Protein
levels of Arnt (upper left panel), Miz-1 (lower left panel), Hif1α (upper right panel) and Hif2α (lower right panel) in response to siRNA treatment
and hypoxia were determined by immunoblotting. Immunoblotting for beta-actin was included to control for protein loading. D) U2OS cells were
cultured at normoxia (21% O2) or at hypoxia (1% O2) for the time points indicated, and qRT-PCR analyses for Miz-1 mRNA expression were performed. The
qRT-PCR values in A, B and D were normalized to the housekeeping gene HPRT-1, and are shown as average of two or three independent experiments
performed in duplicates (n = 4 for A and B, n= 6 for D). E) U2OS cells were transfected with siRNA (10 nM) against Miz-1, Hif1α and Hif2α or a negative
control siRNA together with the −35CDKN2B/luc reporter (300 ng) in the presence or absence of an Arnt expression vector (Arnt/Flag/pCMV, 100 ng) as
indicated. The luciferase activity is presented as average +/− stdev, n = 3. Statistical analyses: (A-B and E) Student’s T-test, (D) ANOVA (Bonferroni); ***p ≤
0.001, **P ≤ 0.01, *P ≤ 0.05, ns: non significant.
Aesoy et al. Molecular Cancer 2014, 13:54 Page 7 of 13
http://www.molecular-cancer.com/content/13/1/54on the proximal promoter during hypoxia. In contrast to
our theory, however, ChIP experiments demonstrated de-
creased enrichment of Myc in response to low O2 pres-
sure (Figure 6A, left panel). Actually, it was previously
reported that Myc is released from the CDKN2B promoter
in hypoxic cells, as well as from the CDKN2A promoter,
which was used as a control in our experiment (Figure 6B
and [22]). CDKN2B is under tight transcriptional control
by multiple signaling cascades, transcription factors andepigenetic mechanisms [32,33], and most likely, other
transcription pathways than those investigated in the
present study are involved in the repression of this gene at
hypoxic conditions.
Discussion
Transcriptional signaling induced by low O2 tension and
irregular Myc expression play crucial roles in tumor devel-
opment and cancer progression [18,20]. Both pathways
Figure 6 Hypoxia leads to release of Myc from the CDKN2B promoter. ChIP experiments were performed on extracts from U2OS cells using
an antibody (Ab) against Myc or preimmune IgG as indicated. The cells were cultured at normoxia (21% O2) or at hypoxia (1% O2) for 4 or
24 hours before harvested. qPCR was performed with primers spanning the proximal (−168/-19) (A, left panel) or distal (−3874/-3744) (A, right
panel) CDKN2B promoter sequences, and primers spanning either the proximal (+6/+106) (B, left panel)) or distal (−2337 /-2158) (B, right panel)
CDKN1A promoter sequences. The results are given as average enrichment of the indicated promoter fragment +/− stdev, n = 6. Statistical
analyses: ANOVA (Dunnett’s T3), **P ≤ 0.01, *P≤ 0.05, ns: not significant. For the IgG control experiments there were no statistically significant
differences detected, apart from on the CDKN2B distal promoter, as indicated in the figure (A, right panel).
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transcriptional regulators converge on promoters of sev-
eral genes encoding cell cycle regulatory factors [22,34-38].
It has been suggested that Hif1α counteracts Myc on the
proximal promoters of CDKN1A, CDKN1B and CDKN2B
by disrupting the complex formation between Myc/Max
and Miz-1 [22,38]. In contrast, Hif2α enhances Myc activ-
ity from these promoters in a renal clear cell carcinoma
cell line overexpressing the von Hippel Lindau factor
(WT-8 cells, [22]). The DNA binding domain of Hifα ap-
pears not to be required for these actions, but the under-
lying biochemistry is not well understood.
The data presented in this study demonstrate that Miz-1
and Arnt can reside in the same protein complex. More-
over, we show that Arnt is enriched on a promoter that is
well documented as a Myc/Miz-1 target [10] and that this
promoter is regulated by hypoxia. These findings are im-
portant as they define a direct physical protein interaction
that integrates these two pathways that are recurrently
dysregulated in cancer cells. Interestingly, our mutational
analyses suggest that Arnt provides a similar interaction
surface for Miz-1 as Myc does [14]. Miz-1 interacts with
different types of proteins [15,16,39], but to our know-
ledge, Arnt is the only bHLH factor demonstrated to inter-
act with Miz-1 besides Myc. Although we were unable to
map the domain of Miz-1 required for interaction withArnt, we anticipate a similar mode of interaction as for the
Myc/Miz-1 complex, with the further implication that
Myc and Arnt might compete for Miz-1 interaction. This
assumption is supported by the observation that Arnt-
induced transcription from the CDKN2B promoter was
suppressed by wild type Myc, but not by a mutated form
(V394D) that is unable to interact with Miz-1, as shown
previously [13,14]. A potential mutual exclusive interaction
of Arnt and Myc with Miz-1 on common target genes
might have considerable functional cellular consequences.
Myc is in complex with Max when it interacts with
Miz-1, and comparably our results possibly suggest that
activation by Arnt on the CDKN2B promoter is dependent
on Hifα, as knockdown of Hifα caused decreased transcrip-
tional capacity by Arnt. The amino acid composition of
helix II in Hif1α and 2α does not suggest that they can
interact directly with Miz-1 in a similar fashion as Arnt and
Myc. We regard it as plausible therefore that regulation of
CDKI encoding genes by Hifα generally is dependent on a
complex formation between Arnt and Miz-1 (although we
were unable to detect a complex consisting of all three
factors in co-IP experiments). Interestingly, Arnt has
been implicated in the transcriptional regulation of
several CDKIs [36,40], of which the majority is also regu-
lated by Miz-1 [15,41]. For instance, Arnt induces expres-
sion of CDKN1B, an established Myc/Miz-1 target gene
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lular carcinoma cells (HCC), Arnt up-regulates CDKN1C
[40], a gene that is also regulated by the Myc/Miz-1 com-
plex [41]. Together with the present study, these studies
suggest that Arnt, via complex formation with Miz-1, may
function as a general anchor for Hifα on CDKI promoters.
Based on our results we propose the following hypoth-
esis (Figure 7): In U2OS cells, and perhaps in other cancer
cells with dysregulated proliferation, we envision that
under normoxia, a transactivating complex consisting of
Miz-1/Arnt and perhaps Hif1α or Hif2α is anchored on
the CDKN2B proximal promoter via the DNA binding do-
main of Miz-1, stimulating expression of CDKN2B. Hyp-
oxia response elements are not required for Arnt/Hifα
complex binding to occur. A transrepressive complex con-
sisting of Miz-1 and Myc/Max will counteract the activa-
tion mediated by the Miz-1/Arnt complex, and we suggest
that the opposite actions of these complexes ensure
adequate levels of CDKN2B in normoxic cells. Upon
hypoxia, the majority of the transactivating Arnt/Hifα
complexes are released from the CDKN2B promoter,
leading to decreased expression. Similarly, Myc is re-
leased from the promoter, and might therefore not be
essential for transcriptional repression from this pro-
moter in the hypoxic state, as it indeed is in normoxic
cells (our results and [10]). Of note is that Gordan et al.
reported that in hypoxic colorectal cancer cells (HCT116),
Myc is released from several CDKI promoters, among
them CDKN2B [22]. The reduced expression of Miz-1 at
low O2 pressure should also contribute to lower CDKN2B
expression, both because of its role as a transactivator and
because the recruitment of Arnt will be diminished. Fu-
ture experiments will establish if Miz-1 is present at the
CDKN2B promoter at hypoxia, influenced by yet unidenti-
fied repressive factors, or whether Miz-1 independent
mechanisms are responsible for decreased CDNK2B ex-
pression as O2 levels falls. The potential biomedical modi-
fications that cause the release of the Arnt/Hifα and Myc/Figure 7 Model based on the presented data. We hypothesize that in U
Hif1α and/or Hif2α is anchored to the CDKN2B proximal promoter via Miz-1
interaction surface on Miz-1, counteracts this activity, and the mutually exclus
normoxia (left). Upon hypoxia, the examined complexes binding at high O2 p
interact with Miz-1 or to act by other means to repress the expression of CDKMax complexes from the CDKN2B promoter during low
oxygen conditions remain to be determined. The release
might be regulated by diverse posttranslational modifi-
cations, e.g. oxygen-dependent hydroxylation, histone-
modifying mechanisms like de-acetylation and/or by
cofactor interactions, as have been described for other
promoters regulated by Myc or Hifα [6,42,43].
Our findings that Arnt activates the CDKN2B pro-
moter and that knockdown of Arnt causes a decrease in
the mRNA level of CDKN2B in U2OS cells are in line
with recent findings in HCC [40]. This study suggested
that Arnt-dependent regulation of cell cycle proteins,
among them CDKN2B, causes HCC stagnancy and de-
creased metastasis and that high intratumoral Arnt ex-
pression is correlated with increased overall survival and
reduced recurrence incidence of HCC patients [40].
CDKN2B also acts as a tumor suppressor in other can-
cer types [44,45]. However the role of Arnt in regulation
of CDKN2B in these cancer types remains to be examined.
Up-regulation of CDKIs in response to hypoxia restricts
cell proliferation in a variety of cancer cell lines, including
U2OS cells [31,35,36,46-48], and Arnt has been implicated
in induced expression of CDKN1B under hypoxic condi-
tions [36]. Our finding that Arnt is released from the
CDKN2B promoter in response to hypoxia, followed by
reduced CDKN2B expression is therefore somewhat con-
tradictory to the overall effects of hypoxia on proliferation
in U2OS cells. However, CDKN2B is also repressed at low
O2 levels in HCT116 cells [1], although hypoxia induces
cell cycle arrest in these cells [38], suggesting that it is the
combined transcriptional changes in cell cycle regulatory
factors that will determine the final proliferative character-
istics of a tumor cell. Intriguingly, the relative expression
of Hif1α and 2α might also affect the proliferation rate
[22]. Taken together, the wealth of studies that exist on
CDK-inhibitors in cancer cell lines clearly point to that ex-
pression of these proteins is differently regulated in differ-
ent cell lines [31,35,36,46-48]. Although this study was2OS cells under normoxia, a complex consisting of Miz-1/Arnt and
. A repressive complex of Myc/Max, which competes for the same
ive interaction of these complexes ensures adequate levels of CDKN2B at
ressure leave the CDKN2B promoter, allowing yet unknown factors to
N2B (right).
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tween Miz-1 and Arnt might be of importance in cell
cycle progression in other cancer cells, however not ne-
cessarily for the regulation of CDKN2B. These cell-type
and gene-specific effects are intriguing and possibly reflect
the many different ways cancer cells adapt in order to sur-
vive, and underscore the necessity to analyze the molecu-
lar pathways controlling cell cycle progression in diverse
biological settings.
Conclusions
In conclusion, our finding that Arnt and Miz-1 reside in
the same protein complex directly integrates hypoxia
and Myc-dependent signaling pathways. This direct link
between the HIF and Myc pathways may have important
implications for understanding their roles in cell cycle
progression and cancer development.
Methods
Plasmid constructs
The mutations in helix II of Arnt, T115D/S126A de-
noted “2xmut” and L114A/T115D/R118G/S126A denoted
“4xmut”, were constructed using the Quick Change XL
Site-directed Mutagenesis Kit (Stratagene). ArntΔbHLH
(deleted of amino acids 67–146) has been described previ-
ously [49,50] as has the plasmid Arnt/pECFP-C1 [51] and
the luciferase reporter construct -35CDKN2B /Luc [25]
(kindly provided by Dr. XF Wang (Pharmacology and
Cancer Biology, Duke University School of Medicine,
Durham, NC, USA). Myc/pcDNA3 was kindly provided
by Dr. F. Haenel (Hans-Knöll-Institut für Naturstoff-
Forschung, Department of Cell and Molecular Biology,
07745 Jena, Germany), and Miz-1/pcDNA3 by Dr. L.G.
Larsson (Department of Microbiology, Tumor and Cell
Biology, Karolinska Institutet, Stockholm, Sweden).
Yeast two-hybrid assay
The Matchmaker GAL4 Two-hybrid System 3 (Clontech)
was used to identify Arnt-interacting proteins from a cDNA
library prepared from Y1 mouse adrenocortical tumor cells
using the pCMV-ScriptXR cDNA library construction kit
(Agilent Technologies, Stratagene Products Division). Arnt
deleted of its transactivation domain (Q) was fused to
the GAL4 DNA-binding domain of pGBKT7 (ArntΔQ/
pGBKT7, amino acid 1–618). The Y1 cDNA-library was
expressed as fusion proteins with the GAL4 activation
domain of pGADT7. The Saccharomyces cerevisiae strain
AH109 was transformed with the plasmids and positive
clones were selected based on their ability to grow at high
stringency on synthetic dropout plates lacking adenine,
leucine, tryptophan and histidine. To verify for protein in-
teractions the positive colonies were restreaked on selec-
tion media as described in the manufactures protocol
(Matchmaker GAL4 Two-hybrid System 3, Clontech).Cell cultures
The human osteosarcoma U2OS (ATCC: HTB-96™) and
HEK293 (ATCC: CRL-1573™) cell lines were cultured in
high glucose DMEM (D5786, Sigma) supplemented with
10% bovine calf serum, penicillin (100 units/ml) and
streptomycin (100 mg/ml) (Sigma). The HEK293-EBNA
cell medium was supplemented with 25 mM HEPES. The
cells were maintained in 5% CO2 humidified atmosphere
at 37°C. For hypoxic condition, the cells were cultured at
1% O2 for the time points indicated in the figures.
Cell transfection
For transient transfection experiments, U2OS cells were
plated at a density of 6.5×104 cells per well onto 12-well
plates and transiently transfected the following day using
XtremeGene9 (Roche). Cells were transfected with reporter
plasmid (0.3 μg, −35CDKN2B/Luc) and expression plas-
mids (0.1 ug) as indicated in the figures. The total amount
of DNA was kept constant by compensating with the plas-
mid psp70 (New England Biolabs). 24 hrs after transfection
start, the cells were washed once with PBS and lysed in
luciferase lysis buffer (10 mM Tris–HCl pH 8.0, 4 mM
EDTA, 150 mM NaCl, 0.65% NP40). Cell extracts were
then assayed for luciferase activity on a LUCY-3 lumin-
ometer (Anthos, Austria). Co-immunoprecipitation (co-IP)
assays were conducted using Cos-1 cells. The cells were
grown in 100 mm dishes to 70–80% confluency and trans-
fected with indicated plasmid combinations using X-treme
Gene 9 (Roche). The manufacture’s protocol was followed
using a total amount of 5 μg plasmid per dish. Transfected
cells were incubated for 36 hours at 5% CO2 in 37°C before
preparation of whole cell extract. The cells were washed
with ice-cold PBS before lysis buffer (25 mM Hepes,
100 mM NaCl, 5 mM EDTA, 20 mM glycerol phosphate,
0.5% Triton, 20% glycerol; 300 μl) containing protease in-
hibitors (100 μM (Na3VO4), 2 mM DTT, 1 mM PMSF,
5 μg/μl aprotinin and 5 μg/μl leupeptin)) was added. The
extracts were then sonicated (2 × 5 sec/amplitude 40), and
centrifuged at 13000 rpm (16000 × g) for 5 minutes at 4°C
to pellet cell debris. The supernatants were stored at −80°C.
Co-immunoprecipitation assay
Cell lysates (800 μg total protein in a volume of 400 μl
lysis buffer; see above) were pre-cleared with recombinant
Protein G Agarose (10 μl, cat #15920-010, Invitrogen).
Anti-GFP saturated rProtein G Agarose was prepared by
incubating 50/50 rProtein G Agarose/TBS slurry (800 μl)
with anti-GFP (56 μg) and incubated for 2 hours on a rota-
tion platform at 4°C. The precleared extracts were then in-
cubated with the anti-GFP saturated rProtein G-Agarose
on a rotating platform o/n at 4°C. The beads were vigor-
ously washed three times with ice-cold lysis buffer. 2×
loading buffer (30 μl; 125 mM Tris–HCl pH 6.8, 4% (w/v)
SDS, 20% (w/v) Glycerol and 0.004% (w/v) BromPhenol
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bated at 95°C for 5 minutes. Proteins were resolved by 8%
SDS-PAGE and subjected to immunoblotting.
Immunoblotting
The co-IP membranes were incubated with Flag antibody
(1/3000, diluted in 1× PBS-T (0.1% (v/v) Tween in 1 ×
PBS), (M2; Stratagene)) or GFP antibody (1/3000, diluted
in 1 × PBS-T, (JL-8; BD Biosciences)), and subsequently
with an HRP-conjugated goat anti-mouse secondary anti-
body (1/10000 in 1× PBS-T) using the Supersignal Che-
moluminiscent substrate (Thermo scientific) for detection.
For visualization of the immunostaining patterns, the
membranes were immediately exposed in a Luminescent
Image analyzer (LAS 3000, Fujifilm) for 1–15 minutes.
Protein levels of Arnt, Miz-1, Hif1α and Hif2α upon their
downregulation by specific siRNA were also analysed by
immunoblotting using antibodies against Arnt [52], Miz-1
(Santa Cruz), Hif1α (Abcam), Hif2α (Abcam) and beta-
actin (Abcam). CDKN2B expression was detected using
the C-20 antibody from Santa Cruz (sc-612).
Cellular localization assay
The assay was performed essentially as described [51].
Briefly, HEK293 cells were grown on cover slips and
transfected with the expression plasmids Flag/Miz-1 and
pECFP/Arnt using the Lipofectamine Reagent (Invitrogen).
24 hours after transfection, cells were fixed in 4% parafor-
maldehyde/PBS for 15 min at RT. Blocking was performed
with 10% FBS/PBS for 15 min at RT. Cells were then sub-
jected to incubation with anti-Flag [1:100 (M2; Stratagene)
in 1% BSA/0.1% Triton-X100/PBS] and Texas-red conju-
gated goat anti-mouse antibody (Molecular Probes). Cells
were washed 4× for 10 min with PBS and subjected to con-
focal laser scanning microscopy.
Chromatin immunoprecipitation assay (ChIP)
U2OS cells were cultured at 21% O2 or reduced O2 (1%
O2) for 4 or 24 hours, and ChIP analyses combined with
quantitative PCR were performed as previously described
[53] using antibodies against Arnt [52], Myc (Santa Cruz)
or IgG (Jackson ImmunoResearch). PCR primers flanking
the proximal promoter of the CDKN2B gene (−168/-19)
were F: 5′- cgcatgcgtcctagcatctttg -3′ and R: 5′- gaattccgt
tttcagctgggcc -3′ giving a product of 149 bp. Distal
CDKN2B promoter primers (−3874/-3744) were F: 5′-
ggtgggccctaatccaatctgac -3′ and R: 5′- gcacatggccatcc-
tactgctg -3′ giving a product of 130 bp (see [25] for nucleo-
tide numbering of the CDKN2B promoter). PCR primers
flanking the proximal promoter of the CDKN1A gene
(+6/+106) were F: 5′- tgtgtgagcagctgccgaagtc -3′ and R:
5′- tgccgccgctctctcacct -3′ giving a product of 100 bp. Dis-
tal CDKN1A promoter primers (−2337 /-2158) were F: 5′-
catccctatgctgcctgcttcc -3′ and R: 5′- cctgtctcctaccatccccttcct-3′ giving a product of 179 bp. Primers spanning the HRE
site of the PGK-1 promoter (−75/+101) were F: 5′-
gacagcgccagggagcaatg -3′ and R: 5′- gct ccggaggcttgcagaatg
-3′ giving a product of 176 bp. The comparative Ct method
was used for relative quantification of target DNA amplifica-
tion using SYBR Green.
RNA interference experiment
U2OS cells were transfected with control siRNA (10 nM;
5′- UUCUCCGAACGUGUCACGU -3′) or siRNA against
Arnt (5′-GGAACAAGAUGACAGCCUATT -3′), Miz-1
(5′- GCCUCAUCAGCCUGCUGAATT -3′), Hif1α (5′- G
AAGAACUAUGAACAUAAATT -3′) and Hif2α (5′- CG
GAUAGACUUAUUGCCAATT -3′) (Qiagen) using the
HiPerFect transfection reagent (Qiagen) according to the
manufacturer’s instructions. The cells were cultured for
48 hours and then placed at 21% or 1% O2 for 6 hours be-
fore harvested.
Quantative RT-PCR
RNA was prepared from U2OS cells using Trizol (Life
Technologies). RNA (1 μg) was reversely transcribed using
Superscript II Reverse Transcriptase kit (Life Technologies)
according to the manufacturer’s recommendations. Taq-
Man quantitative RT-PCR was performed using the ABI
7300 system with TaqMan master mix and pre-design pri-
mer/probes for human Arnt, Miz-1, Hif1α and Hif2α
(Arnt: cat# Hs01121918_m1, Miz (ZBTB17) cat#: Hs0111
4794_g1, HIF1α cat#: Hs00153153_m1, HIF2α cat#: Hs0
1026142_m1, CDKN2B cat#: Hs00793225_m1, PGK-1 cat#
Hs00943178-g1, HPRT cat#: 4326321E; Applied Biosys-
tems). Hypoxanthinephophoribosyltransferase (HPRT) was
used as an endogenous control in ΔΔCT analyses. All mea-
surements were performed twice in duplicates.
Statistics
One-way analysis of variance (ANOVA) followed by
Bonferroni adjustment was used for multiple comparisons
of data presented in Figures 2B, 3B, 4B and 5D. ANOVA
with Dunnett’s T3 adjustment was used when variances
were unequal (Figures 2C, 3A and C, 4C, 6A and B). Stu-
dent’s t-test was used in Figures 2A, 5A, B and E.
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